47AA Preclinical Only
FOXO4-DRI
A D-amino acid retro-inverso senolytic peptide that selectively clears zombie (senescent) cells by disrupting the FOXO4–p53 survival axis; all efficacy data is preclinical.
In Plain English: Senescent 'zombie' cells stop dividing but refuse to die, releasing inflammatory signals that accelerate aging. FOXO4-DRI is a mirror-image peptide (all D-amino acids, read backwards) that blocks the protein handshake keeping those zombie cells alive—specifically the FOXO4–p53 interaction—forcing their self-destruction via apoptosis while leaving healthy cells unharmed. Mouse studies show restoration of kidney function, fur density, physical fitness, testosterone production, and reduced fibrosis after treatment. No human trials exist.
Research Maturity
Preclinical Only (308 results in PMC as of May 2026; 10+ direct FOXO4-DRI studies since 2017+ Studies)
Quick Facts
Focus
Aging Research
Cellular Senescence
Route
IV
SubQ
Origin
Synthetically designed D-retro-inverso analog of a FOXO4 fragment. First described by Baar et al. (Cell, 2017). Also known as Proxofim.
Mechanism
Competitively binds the TAD2 domain of p53, displacing FOXO4 from the FOXO4–p53 nuclear complex. Freed p53 undergoes cytoplasmic translocation and activates caspase-3/7-dependent apoptosis exclusively in senescent cells, which overexpress FOXO4. The all-D retro-inverso backbone confers protease resistance and extends plasma stability ~10–100-fold versus the L-amino acid parent.
Outcome
Selective clearance of senescent cells; preclinical restoration of renal function, testosterone output, physical performance, pulmonary architecture, and skin/fur quality in aged rodents.
Safety Flags & Warnings
No Human Clinical Data
FOXO4 Expressed in Cardiac & Muscle Tissue
High Cost / Dose Burden
Injection Site Reactions
Possible Stressor Effect
Always consult a licensed physician. Research purposes only.
€25.0 / mg
